Rethinking phase 2 trials in amyotrophic lateral sclerosis

Overview of attention for article published in Brain, December 2024

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (94th percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

news: 1 news outlet
twitter: 12 X users

bluesky: 13 Bluesky users

Readers on

mendeley: 18 Mendeley

So far, Altmetric has seen 17 Bluesky posts from 13 Bluesky users, with an upper bound of 3,290 followers.

RP @mndaus-research.bsky.social: Rethinking phase 2 trials in amyotrophic lateral sclerosis academic.oup.com/brain/articl... Well-thought out discussion - basically if you want to run 6-month Phase 2 trials - use biomarkers for your go/no-go decision. …

Rethinking phase 2 trials in amyotrophic lateral sclerosis academic.oup.com/brain/articl... Well-thought out discussion - basically if you want to run 6-month Phase 2 trials - use biomarkers for your go/no-go decision. If you want to use ALSFRS-R - you…

Well, this is upsetting. But no worries; we’re only dying out here. #ALS #MND https://bsky.app/profile/did:plc:ioatghzqu5kmyphyou32rmuw/post/3lcxjsqc2tc2x

RP @rpavaneijk.bsky.social: New paper to reflect on the main challenges in phase 2 #ALS #MND trials. Key issues relate too short study durations, reliance on the wrong outcome measures, absence of biomarkers, statistical issues, over-interpretation of '…

This page shows the most recent Bluesky posts that mention this research output. Click here to find out how to access more activity, including 13 additional Bluesky posts.